Brief: HLS Therapeutics Q2 Loss Per Share $0.20

HLS Therapeutics

06/08/2020 12:22

Aug 6 (Reuters) - HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS ANNOUNCES Q2 2020 FINANCIAL RESULTS
    * QTRLY REVENUE WAS $12.6 MILLION COMPARED TO $13.6 MILLION
IN Q2
2019
    * Q2 LOSS PER SHARE $0.20
    * PRESIDENT AND COO GILBERT GODIN HAS BEEN APPOINTED TO
SUCCEED
CEO GREG GUBITZ WHO WILL RETIRE ON OCTOBER 1, 2020

Source text for Eikon:  ID:nCNWMFWlfa 
Further company coverage:  HLS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))